Selutaront, a novel highly selective TAAR1 agonist with favorable drug-like properties, represents a promising candidate for schizophrenia treatment and provides mechanistic insights into TAAR1-targeted therapy. The gene discussed is TAAR1; the disease is schizophrenia.